Back to search results

Cefotetan for E. coli Infections

This study is looking at how well cefotetan works compared to standard antibiotics for treating E. coli infections, specifically those that cause bloodstream infections (bacteremia) or urinary tract infections. It's a pilot study, meaning it's a smaller, initial study to gather information. You might be able to join if you are 18 or older, have an E. coli bloodstream infection from a urinary source, and started antibiotics for an acute illness within the last 48 hours. The main goal is to see if cefotetan leads to successful treatment (clinical success) within 30 days. The study is currently unclear about its recruitment status.

Study design
This is a single-center pilot study that will randomly assign about 84 participants to receive either cefotetan or standard antibiotic therapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 30 days after randomization to determine clinical outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07318584

Cefotetan Therapy for Escherichia Coli Infections

Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatment
Oregon Health and Science University
~84 participants
Updated 2026-01-06 on ClinicalTrials.gov
What's tested:CefotetanCarbapenemsBeta Lactam Antibiotics

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical success
Measured over From randomization through 30 days.

Conditions

E Coli Infection
ESBL Producing E.Coli

Explore related trials

Escherichia coli Infection

NCT07318584

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Oregon Health & Science University

    Portland, Oregonstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Kristina L. Bajema
[email protected]
503-494-1384
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Identified within 48 hours of inpatient antibiotic administration for acute illness.
Patient or legally authorized representative are able to provide informed consent for participation in the study.
Monomicrobial E. coli bacteremia with a genitourinary source.
Isolate susceptible to both ertapenem and cefotetan (ESBL infections) or ceftriaxone and cefotetan (non-ESBL infections).

Exclusion

Allergy to cefotetan.
History of cephalosporin-associated hemolytic anemia.
Allergy to ertapenem or meropenem (among patients with ESBL E. coli infections).
Allergy to ceftriaxone (among patients with non-ESBL E. coli infections). Includes allergy to antibiotics with a similar structure expected to confer cross reactivity to ceftriaxone (cefotaxime, cefpodoxime, ceftazidime).
Admission within 30 previous days.
Any bacteremia with the same organism in the previous 90 days.
Pregnant or breastfeeding.
Moderately to severely immunocompromised, including solid organ or stem cell transplant, hematologic malignancy, active chemotherapy.
Admission with neutropenic fever.
Severe illness, including shock and/or intensive care unit admission.
Inability to complete at least 72 hours of appropriate parenteral therapy, including at least 1 dose cefotetan for patients randomized to the treatment arm or at least 1 dose of appropriate parenteral therapy following randomization for patients assigned to the standard of care arm.

What this trial measures

  • Clinical successFrom randomization through 30 days.

    Absence of death, recurrent E. coli, bacteremia, or need for antibiotic treatment for recurrent E.coli genitourinary infection.